Cardiac natriuretic peptides - Hope or hype?

Journal of Clinical Pharmacy and Therapeutics

Volumn 26, Issue 1, 2001, Pages 15-31

  Venugopal, Joshi ^a,b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

ANP; BNP; Natriuretic; NEP

Indexed keywords

7 (2 MERCAPTOMETHYL 3 PHENYLPROPIONAMIDO)HEPTANOIC ACID; ADENYLATE CYCLASE; ADRENALIN; ALDOSTERONE; AMYLOID BETA PROTEIN; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR RECEPTOR; BRAIN NATRIURETIC PEPTIDE; CANDOXATRILAT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FUROSEMIDE; GLUCAGON; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HS 142 1; INSULINASE; ISOPRENALINE; KELATORPHAN; MEMBRANE METALLOENDOPEPTIDASE; N (1 CARBOXY 3 PHENYLPROPYL)PHENYLALANYLISOSERINE; NATRIURETIC PEPTIDE TYPE C; PHOSPHORAMIDON; RENIN; THIORPHAN; UNINDEXED DRUG; VASOPRESSIN;

AMINO ACID SEQUENCE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR AUTOREGULATION; CLINICAL TRIAL; DRUG CLEARANCE; DRUG COST; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVATION; GENE THERAPY; HEART ATRIUM MUSCLE; HEART FAILURE; HEART INFARCTION; HORMONAL REGULATION; HUMAN; HYPERTENSION; LIVER CIRRHOSIS; MUSCLE STRETCHING; NATRIURESIS; NONHUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TACHYCARDIA; URINARY EXCRETION; VASODILATATION;

ALZHEIMER DISEASE; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR DISEASES; HUMANS; LIVER CIRRHOSIS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 0035082493     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2001.00322.x     Document Type: Review

References (106)

1. Heart atrial granularity: Effects of changes in water-electrolyte balance
2. Responses of plasma catecholamines, renin-angiotensin-aldosterone system and atrial natriuretic peptide to exercise in patients with essential hypertension
3. Atrial natriuretic peptide: Synthesis, release, and metabolism
4. The effect of a human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects
5. Purification of complete amino acid sequence of Alpha-Human atrial natriuretic peptide
6. A new natriuretic peptide in porcine brain
7. C-type natriuretic peptide (CNP): A new member of natriuretic peptide member family identified in porcine brain
8. Plasma and urine levels of uroguanylin, a new natriuretic peptide in nephrotic syndrome
9. Comparative bioactivity of atrial and brain natriuretic peptides in an ovine model of heart failure
10. Vasoactive peptides
11. Atrial natriuretic peptide: Pathophysiological considerations
12. Atrial natriuretic factor-like peptide and its pro-hormone within single cell organism
13. Atrial natriuretic peptide hormonal system in plants
14. Brain natriuretic peptide: Identification of a second natriuretic peptide in human aqueous humour
15. Type B and type C natriuretic peptide receptors modulate intraocular pressure in the rabbit eye
16. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure
17. Preserved atrial natriuretic peptide secretory function after cardiac transplantation
18. Normalisation of circulating atrial natriuretic peptides in cardiac transplant recipients
19. Congestive heart failure in diabetes with hypertension may be due to uncoupling of the atrial natriuretic peptide receptor-effector system in the kidney basolateral membrane
20. Regulation of natriuretic peptide (Urodilatin) release in a human kidney cell line
21. Changes in plasma atrial and ventricular natriuretic peptide concentrations after transfer of eels from freshwater to seawater or vice versa
22. Elevated plasma atrial natriuretic peptide levels after occlusion of the thoracic aorta
23. Atrial natriuretic peptide release during myocardial ischaemia induced by percutaneous transluminal coronary angioplasty
24. Rapid changes of atrial natriuretic peptide concentration during percutaneous transluminal coronary angioplasty
25. Renal, endocrine, and cardiovascular responses during head-out water immersion in leg less men
26. Enhanced brain natriuretic peptide response to peak exercise in heart transplant recipients
27. Control of atrial natriuretic factor release in conscious dogs
28. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study
29. Effect of the beta 1-blocker/beta 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients
30. Angiotensin-2 induced hypertension: Effects on central and peripheral atrial natriuretic peptide
31. Effect of atrial natriuretic peptide (8-33-met ANP) in patients with hypertension
32. How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines
33. The role of calcium in the response of cardiac muscle to stretch
34. Normalisation of left ventricular mass & associated changes in neurohormones & atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension
35. Inhibition of atrial natriuretic peptide (ANP) C receptor expression by antisense oligodeoxynucleotides in A10 vascular smooth-muscle cells is associated with attenuation of ANP-C-receptor-mediated inhibition of adenylyl cyclase
36. Chromosomal distribution of three members of the human natriuretic peptide receptor/guanylyl cyclase gene family
37. Receptor selectivity of natriuretic peptide family, Atrial natriuretic peptide, Brain natriuretic peptide and C-type natriuretic peptide
38. Downregulation of natriuretic peptide C-receptor protein in the hypertrophied ventricle of aorta venocaval fistula rat
39. C-type natriuretic peptide: The endothelial component of the natriuretic peptide system
40. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs functional cardiorenal responses to receptor antagonism
41. Atrial natriuretic peptide-C receptor and membrane signalling in hypertension
42. Atrial natriuretic peptide inhibits evoked catecholamine release by altering sensitivity to calcium
43. Metabolic clearance rate and plasma half life of alpha human atrial natriuretic peptide in man
44. Disappearance of atrial natriuretic factor from circulation in the rat
45. Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxicity
46. Characterisation of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex
47. An intracellular protein that binds Amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease
48. Alzheimer's peptide kills cells of retina in vivo
49. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation
50. Cellular mechanisms of the clearance function of type C-receptors of atrial natriuretic factor
51. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide and c-type natriuretic peptide
52. Prolonged stability of BNP, importance for non-invasive assessment of cardiac function in clinical practice
53. Role of atrial natriuretic polypeptide for exaggerated natriuresis in essential hypertension
54. Biochemical detection of left ventricular systolic dysfunction
55. Two-year time course and significance of neurohumoral activation in the Survival and ventricular enlargement
56. Plasma brain natriuretic peptide concentrations predict survival after acute Myocardial Infarction
57. Brain and atrial natriuretic peptides in patients with ischemic heart disease with and without heart failure
58. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide
59. Plasma n-terminal atrial natriuretic peptide predicts hospitalisation in patients with heart failure
60. Plasma BNP measurement in a multiphasic health screening programme
61. Enhancing and evaluating diagnostic accuracy
62. Meta-analysis of pap test accuracy
63. Predictive properties of serum prostate-specific antigen testing in community based setting
64. Hemodynamic correlates of atrial natriuretic peptide concentration in unselected patients with heart disease of different etiologies
65. Nitric oxide, atrial natriuretic peptide and cGMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts
66. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells
67. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts
68. Interaction of intravenous atrial natriuretic factor with frusemide in patients with heart failure
69. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction
70. Diagnostic value of b-type natriuretic peptide concentrations in patients with acute myocardial infarction
71. Norepinephrine & atrial natriuretic peptide responses to exercise testing in rehabilitated and nonrehabilitated men with ischemic cardiomyopathy after healing of anterior wall acute myocardial infarction
72. New insights into the cardiac natriuretic peptides
73. Prognostic value of N-terminal natriuretic factor plasma levels measured within first 12 hours after myocardial infarction
74. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man
75. N-terminal proatrial natriuretic factor an independent predictor of long term prognosis after myocardial infarction
76. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction
77. Expression and distribution of brain natriuretic peptide in human right atria
78. Comparison of secretion between A-type and B-type natriuretic peptides in patients with old myocardial infarction
79. Comparison of atrial natriuretic peptide versus nitroglycerine for reducing blood pressure in acute myocardial infarction
80. Atrial natriuretic peptide and nitric oxide in children with pulmonary hypertension after surgical repair of congenital heart disease
81. Impaired vasodilatory response to atrial natriuretic peptide during atherosclerosis progression
82. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in dahl salt-sensitive rats
83. Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells
84. Atrial natriuretic polypeptide as a potent antigrowth factor of endothelial cells
85. Salt resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide
86. Plasma levels of atrial natriuretic peptide in normal and hypertensive pregnancies: A meta-analysis
87. Differential regulation of natriuretic peptide genes in infarcted rat hearts
88. Curative effects of highly active atrial natriuretic peptide (haANP) on severe pregnancy induced hypertension
89. Antihypertensive effects of highly active atrial natriuretic peptide (haANP) infusion in patients with pregnancy induced hypertension
90. Treatment of intra operative hypertension with Enflurane, Nicardipine or human Atrial Natriuretic Peptide: Haemodynamics and renal effects
91. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension
92. Dissociation of plasma atrial natriuretic peptide responses to upright posture and frusemide administration in patients with normal, low renin essential hypertension and primary aldosteronism
93. Effects of carvedilol on atrial natriuretic peptide, catecholamines and hemodynamics in hypertension at rest and during exercise
94. Essential hypertension: Renin and aldosterone, heart attack and stroke
95. Hormonal & renal responses to atrial natriuretic peptide infusion in low-renin hypertension
96. Antagonism between the vascular renin-angiotensin and nariuretic peptide systems in vascular remodelling
97. Effects of atrial natriuretic peptide on left ventricular function in hypertension
98. Natriuretic peptide family as a novel antimigration factor of vascular smooth muscle cells
99. Effect of natruretic peptide family on oxidised LDL induced migration of human coronary artery smooth muscle cells
100. The kidney in chronic liver disease: Circulatory abnormalities, renal sodium handling and role of natriuretic peptides
101. Serum endothelin and atrial natriuretic peptide in cirrhotic patients with ascites and hepatorenal syndrome
102. Age-related responses of vasoactive factors during acute exercise
103. Truncated atrial natriuretic factor analogs retain full agonist activity
104. The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors
105. The guanylate cyclase coupled natriuretic peptide receptor: A new target for prevention of cold ischemia-reperfusion damage of the rat liver